Skip to main content
S&P 5007,722.72+0.73%DOW51,176.96+0.49%NASDAQ27,190.86+1.19%BTC$84,654.00-0.13%ETH$2,677.39-1.09%GOLD$4,172.10-0.72%OIL$91.26-1.73%
Smart Investors Daily
SID Premium
QT

NASDAQ · QTRX

Quanterix Corporation

Healthcare · Medical - Devices

$3.64

Up+$0.23 (+6.74%)

Updated Oct 3, 2026, 3:48 PM

SID Score

4.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
352.9M
P/E ratio
-4.17
Dividend yield
0.00%
52-week range
$2.15 – $8.77
Volume
590.81K
Avg. volume
639.37K

Price performance · QTRX

QTRX price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 2, 2026

QTRX closed at $3.64 after 20 trading sessions, up 35.32% for the selected period.

Last close
$3.64
Period change
+35.32%
Period low
$2.50
Period high
$3.71
Daily close
View OHLC price history
QTRX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 2, 2026$3.44$3.69$3.44$3.64590.81K
Oct 1, 2026$3.72$3.72$3.375$3.41629.49K
Sep 30, 2026$3.67$3.72$3.59$3.71545.39K
Sep 29, 2026$3.52$3.71$3.454$3.67623.45K
Sep 28, 2026$3.25$3.6735$3.23$3.521.04M
Sep 25, 2026$3.23$3.29$3.105$3.27563.77K
Sep 24, 2026$3.15$3.22$3.041$3.18374.22K
Sep 23, 2026$3.17$3.1976$3.03$3.16423.78K
Sep 22, 2026$3.05$3.21$3.03$3.19424.9K
Sep 21, 2026$3.13$3.175$3.005$3.04627.56K
Sep 18, 2026$3.12$3.14$3.00$3.071.05M
Sep 17, 2026$2.94$3.19$2.90$3.12955.75K
Sep 16, 2026$2.72$2.955$2.6601$2.91924.87K
Sep 15, 2026$2.50$2.79$2.495$2.721.6M
Sep 14, 2026$2.50$2.685$2.37$2.506.1M
Sep 11, 2026$2.52$2.59$2.50$2.56323.04K
Sep 10, 2026$2.60$2.625$2.49$2.50456.06K
Sep 9, 2026$2.70$2.715$2.61$2.65267.38K
Sep 8, 2026$2.64$2.83$2.61$2.73647.37K
Sep 4, 2026$2.58$2.695$2.54$2.69274.59K

Latest QTRX news

The latest Smart Investors Daily articles mentioning QTRX.

Stock researchCompany · Overview

QTRX research

Overview

Company profile and research snapshot.

Company profile

Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$18.67
Implied upside
—
Analysts
—
QTRX recent ratings
DateFirmRatingTarget
Aug 17, 2026Canaccord GenuityHold—
Aug 11, 2026TD CowenHold—
May 7, 2026TD CowenHold—
Apr 20, 2026Canaccord GenuityHold—
Dec 22, 2025Canaccord GenuityHold—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 25, 2026

Quanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026

BILLERICA, Mass., September 25, 2026--Quanterix Corporation (NASDAQ: QTRX) today reported significant progress on the Content Innovation Engine it introduced at the American Association for Cancer Research (AACR) Annual Meeting 2026, highlighting new updates at the European Society for Spatial Biology (ESSB) September 28-October 1, 2026. This progress underscores Quanterix's growing leadership in spatial biology content, delivering the assays researchers need to do more pivotal work. Built on th

Yahoo · Sep 17, 2026

Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BILLERICA, Mass., September 17, 2026--Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced that on September 15, 2026, inducement grants (the "Inducement Grants") were made to James Gute, the recently appointed Chief Commercial Officer of the Company, and two other employees in connection with the commencement of their employment. The Inducement Grant to Mr. Gute consisted of 260,315 restricted stock Units ("RSUs") representing 260,315 shares of Q

Yahoo · Sep 14, 2026

Quanterix Names Dr. Yuri Fesko Chief Medical Officer

BILLERICA, Mass., September 14, 2026--Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that accomplished physician executive Dr. Yuri Fesko has been appointed Chief Medical Officer of the company. In this new role, he will provide medical and clinical leadership across Quanterix, partnering closely with the company’s Diagnostics, Scientific, R&D, Regulatory, and Commercial teams, to advance Quanterix’s innovative technologies and applications.

Yahoo · Sep 4, 2026

Global Multiplex Assays Market 2026 Edition - Consumables Dominate Multiplex Assays with 68% Market Share

The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with a 34% share, while Asia Pacific is the fastest-growing region at 15.5%; India is forecast to expand at 16.9%. Consumables account for 68% of sales and protein multiplex assays hold 42%. Growth is driven by precision medicine, companion diagnostics, biomarker R&D, molecular diagnostics and laboratory automation. Key players include Thermo Fisher

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By